TCG Crossover GP II, LLC bought $3.0M of Surrozen (SRZN)
Executed Mar 23, disclosed Mar 26, 2 days later.
Over the 21 trading sessions from the disclosed entry session (Mar 25), the stock returned +20.7% (delay-adjusted); from the execution session (Mar 23), +21.7%. Derived: entry at the session's open, exit at the close 20 sessions later.
TCG Crossover GP II, LLC (10% owner) filed 4 Form 4 reports as a reporting entity in the trailing twelve months (3 purchases, 1 sale), most often in Surrozen, Inc. (SRZN). Across 3 priced purchase filings, the average 21-session return was +12.8% from execution and +16.1% from disclosure (delay-adjusted; derived). The largest single filing was $6.9M of SRZN (325,000 sh across 2 lots, as filed), executed Jul 22.
Healthcare · Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→325,000 sh across 2 lots
Exec Jul 22
Filed Jul 24 · 9:00 PM ET SRZNPURCHASE Surrozen, Inc. $1.2M
47,807 sh across 4 lots
Exec Mar 12
Filed Mar 16 · 7:05 PM ET SRZNPURCHASE Surrozen, Inc. $419K
17,763 sh across 2 lots
Exec Feb 11
Filed Feb 13 · 4:19 PM ET